Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 – Pharmacokinetic, pharmacogenetic and clinical aspects
2026/07/01 by Xenia M. Hart, Gerhard Gründer, Stefan Unterecker +47
paper · doi:10.1055/a-2860-7861
crossref issued 2026/07/01 · crossref published 2026/07/01 · crossref published-print 2026/07/01 · crossref published-online 2026/07/02 · crossref created 2026/07/02 · crossref deposited 2026/07/28 · crossref indexed 2026/08/05
Abstract
Abstract TDM involves measuring and interpreting drug concentrations in blood plasma or serum to optimize pharmacotherapy. In psychiatry and neurology, TDM is a well-established tool for personalized drug treatments. The AGNP-TDM task force initially published guidelines for best practice TDM in 2004, 2011, and 2017. A fundamental methodological revision has now been carried out on how to determine therapeutic reference ranges and dose-related reference ranges transparently and systematically. In the current edition, 50 experts in neuropsychopharmacology offer a complete update of both ranges for each substance following an evidence-based approach. Various types of data were considered for reference range determination, ranging from meta-analyses to drug concentrations expected under recommended doses. Therapeutic reference ranges are now listed for 160 neuropsychiatric drugs, newly included for 30 drugs and revised for 88 drugs. Expected drug concentrations can be calculated based on a revised formula for 162 drugs. Obligatory TDM (i.e. for dose titration) is strongly recommended for 15 neuropsychiatric drugs and recommended for 39 drugs. TDM is classified as useful for 49 drugs and potentially useful for 62 drugs, indicating that it is recommended in specific clinical situations, such as suspected non-adherence, insufficient clinical response despite recommended doses, relapse during maintenance treatment, and many more. The 2026 update includes practical pharmacogenetic recommendations that are directly relevant to TDM. This work integrates a combination of strategies to guide drug treatments in clinical practice using all available tools. A consistent implementation of TDM and pharmacogenetic recommendations will enhance neuropsychopharmacotherapy, improve patient outcomes, and reduce healthcare costs.
Citations
- Evaluation of antiseizure medication concentration ranges in blood samples using an automated big data approach
- Polyintoxication with cenobamate, perampanel, and carbamazepine: A complex case report
- Evaluation of Cytochrome P450‐Mediated Cannabinoid‐Drug Interactions in Healthy Adult Participants
- Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants
- A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
- An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
- Clinical Value of Emerging Bioanalytical Methods for Drug Measurements: A Scoping Review of Their Applicability for Medication Adherence and Therapeutic Drug Monitoring
- A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy
- Inhibition and induction of CYP enzymes in humans: an update
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update
- <p>Transdermal Asenapine in Schizophrenia: A Systematic Review</p>
- Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
- Extraction Procedures for Hair Forensic Toxicological Analysis: A Mini-Review
- Duloxetine plasma level and antidepressant response
- Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort
- Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
- Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update
- Refutation of the historical evidence for a Hispaniolan macaw (Aves: Psittacidae)
- Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI
- STOPP/START criteria for potentially inappropriate prescribing in older people: version 2
- Prediction of Antidepressant Response to Venlafaxine by a Combination of Early Response Assessment and Therapeutic Drug Monitoring
- Early Improvement and Serum Concentrations of Citalopram to Predict Antidepressant Drug Response of Patients with Major Depression
- Impact of Impaired Renal Function on the Pharmacokinetics of the Antiepileptic Drug Lacosamide
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
- AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
- ISO 15189 Accreditation: Requirements for quality and competence of medical laboratories, experience of a laboratory I
- Prescribing Patterns and the Use of Therapeutic Drug Monitoring of Psychotropic Medication in a Psychiatric High-Security Unit
- Toxicokinetics of Dothiepin: 2 Case Reports
- Anticholinergic Activity of 107 Medications Commonly Used by Older Adults
- Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans
- The Anticholinergic Risk Scale and Anticholinergic Adverse Effects in Older Persons
- Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein
- Clinical implications of Brief Psychiatric Rating Scale scores
- Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
- The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry
- Detection Times of Drugs of Abuse in Blood, Urine, and Oral Fluid
- Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem
- Olanzapine
- The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients
- Statistical methods for assessing agreement between two methods of clinical measurement
- Clinical Pharmacokinetics of Chlordiazepoxide
- Sex Differences in Pharmacokinetics and Pharmacodynamics
- Pharmacokinetics of parenteral and oral melperone in man
- Interindividual Variability of the Clinical Pharmacokinetics of Methadone
- Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function